{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:21:05Z","timestamp":1792099265571,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s11606-018-4801-3","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T17:03:23Z","timestamp":1549472603000},"page":"1039-1042","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction"],"prefix":"10.1007","volume":"34","author":[{"given":"S. L.","family":"Calcaterra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Chadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. D.","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. L.","family":"Morford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H.","family":"Samet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"4801_CR1","unstructured":"Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. 2018."},{"key":"4801_CR2","unstructured":"Administration SAaMHS. Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5068, NSDUH Series H-53). In: Center for Behavioral Health Statistics and Quality SAaMHSA, ed. Rockville, Maryland 2018."},{"key":"4801_CR3","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009(3).","DOI":"10.1002\/14651858.CD002209.pub2"},{"key":"4801_CR4","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ (Clinical research ed). 2017;357:j1550.","journal-title":"BMJ (Clinical research ed)."},{"issue":"3","key":"4801_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Ann Intern Med. 2018;169(3):137\u2013145.","journal-title":"Ann Intern Med."},{"issue":"1","key":"4801_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction (Abingdon, England). 2014;109(1):79\u201387.","journal-title":"Addiction (Abingdon, England)."},{"key":"4801_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","volume":"169","author":"L-T Wu","year":"2016","unstructured":"Wu L-T, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117\u2013127.","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"4801_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/10550887.2010.531672","volume":"30","author":"A Fareed","year":"2011","unstructured":"Fareed A, Vayalapalli S, Stout S, Casarella J, Drexler K, Bailey SP. Effect of methadone maintenance treatment on heroin craving, a literature review. J Addict Dis. 2011;30(1):27\u201338.","journal-title":"J Addict Dis."},{"issue":"4","key":"4801_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","volume":"28","author":"L Amato","year":"2005","unstructured":"Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28(4):321\u2013329.","journal-title":"J Subst Abuse Treat."},{"issue":"10","key":"4801_CR10","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","volume":"2","author":"J Kimber","year":"2015","unstructured":"Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry. 2015;2(10):901\u2013908.","journal-title":"Lancet Psychiatry."},{"issue":"2","key":"4801_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugpo.2009.10.004","volume":"21","author":"RD Bruce","year":"2010","unstructured":"Bruce RD. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int J Drug Policy. 2010;21(2):122\u2013124.","journal-title":"Int J Drug Policy."},{"issue":"8","key":"4801_CR12","doi-asserted-by":"publisher","first-page":"e12411","DOI":"10.5812\/hepatmon.12411","volume":"13","author":"SM Alavian","year":"2013","unstructured":"Alavian SM, Mirahmadizadeh A, Javanbakht M, et al. Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users. Hepat Mon. 2013;13(8):e12411.","journal-title":"Hepat Mon."},{"key":"4801_CR13","doi-asserted-by":"publisher","first-page":"948789","DOI":"10.1155\/2011\/948789","volume":"2011","author":"A Rosenblum","year":"2011","unstructured":"Rosenblum A, Cleland CM, Fong C, Kayman DJ, Tempalski B, Parrino M. Distance traveled and cross-state commuting to opioid treatment programs in the United States. J Environ Public Health. 2011;2011:948789.","journal-title":"J Environ Public Health."},{"key":"4801_CR14","unstructured":"Administration SAaMHS. Legislation, Regulations, and Guidelines. 2018. \n                    https:\/\/www.samhsa.gov\/programs-campaigns\/medication-assisted-treatment\/legislation-regulations-guidelines#DATA-2000\n                    \n                  . Accessed 8\/20\/2018, 2018."},{"key":"4801_CR15","unstructured":"Advisory S. An introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence. Winter 2012."},{"key":"4801_CR16","unstructured":"Substance Abuse and Mental Health Services Administration CfBHSaQ. The N-SSATS Report: Trends in the Use of Methadone and Buprenorphine at Substance Abuse Treatment Facilities: 2003 to 2011. Rockville, MD2013."},{"issue":"8","key":"4801_CR17","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","volume":"105","author":"CM Jones","year":"2015","unstructured":"Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55-e63.","journal-title":"Am J Public Health."},{"key":"4801_CR18","unstructured":"Lenardson M, Jennifer D, Gale M, John A. Distribution of substance abuse treatment facilities across the rural-urban continuum. 2008."},{"issue":"12","key":"4801_CR19","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.2105\/AJPH.2018.304673","volume":"108","author":"JA Barocas","year":"2018","unstructured":"Barocas JA, White LF, Wang J, et al. Estimated prevalence of opioid use disorder in Massachusetts, 2011-2015: a capture-recapture analysis. Am J Public Health. 2018;108(12):1675\u20131681.","journal-title":"Am J Public Health."},{"key":"4801_CR20","unstructured":"Dombrowski K, Crawford D, Khan B, Tyler K. Current rural drug use in the US midwest. J drug Abuse. 2016;2(3)."},{"issue":"2","key":"4801_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/jrh.12141","volume":"32","author":"SM Monnat","year":"2016","unstructured":"Monnat SM, Rigg KK. Examining rural\/urban differences in prescription opioid misuse among US adolescents. J Rural Health 2016;32(2):204\u2013218.","journal-title":"J Rural Health"},{"issue":"19","key":"4801_CR22","first-page":"1","volume":"66","author":"KA Mack","year":"2017","unstructured":"Mack KA, Jones CM, Ballesteros MF. Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas - United States. Morb Mortal Wkly Rep Surveill Summ (Washington, DC : 2002). 2017;66(19):1\u201312.","journal-title":"Morb Mortal Wkly Rep Surveill Summ (Washington, DC : 2002)"},{"issue":"4","key":"4801_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamapsychiatry.2013.4450","volume":"71","author":"SC Sigmon","year":"2014","unstructured":"Sigmon SC. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiatry. 2014;71(4):359\u2013360.","journal-title":"JAMA Psychiatry."},{"issue":"4","key":"4801_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0740-5472(03)00188-0","volume":"25","author":"K Beardsley","year":"2003","unstructured":"Beardsley K, Wish ED, Fitzelle DB, O\u2019Grady K, Arria AM. Distance traveled to outpatient drug treatment and client retention. J Subst Abuse Treat. 2003;25(4):279\u2013285.","journal-title":"J Subst Abuse Treat."},{"key":"4801_CR25","unstructured":"Alderks CE. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003\u20132015 (update). The CBHSQ report: August 22, 2017: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, MD; 2017."},{"issue":"5","key":"4801_CR26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s11920-011-0222-2","volume":"13","author":"EM Oliva","year":"2011","unstructured":"Oliva EM, Maisel NC, Gordon AJ, Harris AHS. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(5):374\u2013381.","journal-title":"Curr Psychiatry Rep."},{"key":"4801_CR27","unstructured":"Abuse S. Federal guidelines for opioid treatment programs. HHS publication no.(SMA) PEP15-FEDGUIDEOTP. 2015."},{"key":"4801_CR28","unstructured":"Hancock C MH, King N, Andrilla H, Larson E, Schou P. Treating the rural opioid epidemic. 2017."},{"key":"4801_CR29","unstructured":"Addiction EMCfDaD. Substitution Treatment - Prescription Regulations. \n                    http:\/\/www.emcdda.europa.eu\/html.cfm\/index41826EN.html\n                    \n                  . Accessed 10\/2\/2018, 2018."},{"key":"4801_CR30","unstructured":"Ontario CoPaSo. Methadone Maintenance Guidelines. In: Ontario CoPaSo, ed. Toronto, Ontario2005."},{"key":"4801_CR31","unstructured":"Ontario CoPaSo. Methadone maintenance treatment: program standards and clinical guidelines. In: Ontario CoPaSo, ed. Toronto, Ontario2011."},{"issue":"4","key":"4801_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.4066\/AMJ.2011.706","volume":"4","author":"BB Chaar","year":"2011","unstructured":"Chaar BB, Hanrahan JR, Day C. Provision of opioid substitution therapy services in Australian pharmacies. Aust Med J. 2011;4(4):210\u2013216.","journal-title":"Aust Med J."},{"key":"4801_CR33","unstructured":"White A, Szukalski J, Watters A, Ransom A. National opioid pharmacotherapy statistics annual data collection: 2011 report. Australian Institute of Health and Welfare; 2012."},{"issue":"4","key":"4801_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2149","volume":"166","author":"P Korthuis","year":"2017","unstructured":"Korthuis P, McCarty D, Weimer M, et al. Primary care\u2013based models for the treatment of opioid use disorder: a scoping review. Ann Int Med. 2017;166(4):268\u2013278.","journal-title":"Ann Int Med."},{"issue":"1","key":"4801_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1370\/afm.2184","volume":"16","author":"RE Cantone","year":"2018","unstructured":"Cantone RE, Fleishman J, Garvey B, Gideonse N. Interdisciplinary management of opioid use disorder in primary care. Ann Fam Med. 2018;16(1):83.","journal-title":"Ann Fam Med."},{"key":"4801_CR36","doi-asserted-by":"crossref","unstructured":"Greer N, Bolduc J, Geurkink E, et al. Pharmacist-led chronic disease management: a systematic review of effectiveness and harms compared with usual care. Ann Intern Med. 2016.","DOI":"10.7326\/M15-3058"},{"issue":"8","key":"4801_CR37","doi-asserted-by":"publisher","first-page":"e0183172","DOI":"10.1371\/journal.pone.0183172","volume":"12","author":"DM Qato","year":"2017","unstructured":"Qato DM, Zenk S, Wilder J, Harrington R, Gaskin D, Alexander GC. The availability of pharmacies in the United States: 2007-2015. PloS one. 2017;12(8):e0183172.","journal-title":"PloS one."},{"key":"4801_CR38","unstructured":"Substance Abuse and Mental Health Services Administration CfSATDoPT. Opioid Treatment Program Directory. 2018. \n                    https:\/\/dpt2.samhsa.gov\/treatment\/directory.aspx\n                    \n                  . Accessed November, 11, 2018."},{"key":"4801_CR39","unstructured":"Jalloh M.. Vaccinations: pharmacists shot at improving community health. Pharm Times. 2016."},{"issue":"5","key":"4801_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","volume":"171","author":"DP Alford","year":"2011","unstructured":"Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425\u2013431.","journal-title":"Arch Intern Med."},{"issue":"4","key":"4801_CR41","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","volume":"11","author":"JR Brooklyn","year":"2017","unstructured":"Brooklyn JR, Sigmon SC. Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. J Addict Med. 2017;11(4):286.","journal-title":"J Addict Med."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-018-4801-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-018-4801-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-018-4801-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T20:04:13Z","timestamp":1580933053000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-018-4801-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4801"],"URL":"https:\/\/doi.org\/10.1007\/s11606-018-4801-3","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]},"assertion":[{"value":"30 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}